Yung Cheng Wu, a Director, acquired 1,000,000 Common Shares at a price of $0.100 and 500,000 Warrants exercisable at $0.150 until June 21, 2020 on an indirect ownership basis for registered holder NFQ Ventures Ltd through a prospectus or prospectus exempt offering on August 18th, 2017. This represents a $100,000 investment into the company's shares and an account share holdings change of 62.5%.
Antibe Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery. Antibe Therapeutics Inc. (ATE) has below median officer and director direct ownership compared to its micro-cap peers in the market, based on our estimate using SEDI data. According to regulatory filings yesterday, one insider has invested a total amount of $100,000.
No Comments